Download PDF
Semin Respir Crit Care Med 2010; 31(4): 501-518
DOI: 10.1055/s-0030-1262218
© Thieme Medical Publishers

Treatment of Sarcoidosis

Catherine A. Lazar1 , Daniel A. Culver1
  • 1Respiratory Institute, Cleveland Clinic Foundation, Cleveland, Ohio
Further Information

Publication History

Publication Date:
27 July 2010 (online)

    Permissions and Reprints

ABSTRACT

Sarcoidosis is an immune-mediated systemic syndrome of unknown etiology. The treatment of the granulomatous inflammation in sarcoidosis is thus dependent on nonspecific suppression of the immune response. Although steroid-sparing approaches have moved to front-line therapy for many other immune-mediated inflammatory diseases, corticosteroids remain the initial treatment of choice for most patients with sarcoidosis due in large part to the clinical variability and high rates of spontaneous remission. Given the heterogeneity of clinical phenotypes between patients, treatment approaches must be individualized. For patients with persistent disease, or for patients who are intolerant of systemic steroids, there are several steroid-sparing immune-modulating medications that have been effective for treating sarcoidosis. Besides immunosuppressives, we will also overview several sarcoidosis-related issues that contribute to patient-reported symptoms, a “sarcoidosis penumbra.” Recognition and judicious therapy for these related issues are often key to optimizing outcomes and quality of life.

KEYWORDS

Sarcoidosis - therapy - corticosteroids - immunosuppressive medications - immunomodulators

REFERENCES

  • 1 Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.  Am J Respir Crit Care Med. 1999;  160 736-755
    PubMedGoogle Scholar
  • 2 Judson M A, Baughman R P, Thompson B W ACCESS Research Group et al. Two year prognosis of sarcoidosis: the ACCESS experience.  Sarcoidosis Vasc Diffuse Lung Dis. 2003;  20 204-211
    PubMedGoogle Scholar
  • 3 Sones M, Israel H L, Dratman M B, Frank J H. Effect of cortisone in sarcoidosis.  N Engl J Med. 1951;  244 209-213
    CrossrefPubMedGoogle Scholar
  • 4 Siltzbach L E. Effects of cortisone in sarcoidosis; a study of thirteen patients.  Am J Med. 1952;  12 139-160
    CrossrefPubMedGoogle Scholar
  • 5 Lynch III J P, Ma Y L, Koss M N, White E S. Pulmonary sarcoidosis.  Semin Respir Crit Care Med. 2007;  28 53-74
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations.  Cardiovasc Drugs Ther. 1996;  10 495-510
    CrossrefPubMedGoogle Scholar
  • 7 Cox C E, Donohue J F, Brown C D, Kataria Y P, Judson M A. Health-related quality of life of persons with sarcoidosis.  Chest. 2004;  125 997-1004
    CrossrefPubMedGoogle Scholar
  • 8 Baughman R P, Sparkman B K, Lower E E. Six-minute walk test and health status assessment in sarcoidosis.  Chest. 2007;  132 207-213
    CrossrefPubMedGoogle Scholar
  • 9 Davidson T A, Caldwell E S, Curtis J R, Hudson L D, Steinberg K P. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients.  JAMA. 1999;  281 354-360
    CrossrefPubMedGoogle Scholar
  • 10 Bing E G, Hays R D, Jacobson L P et al.. Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study.  Qual Life Res. 2000;  9 55-63
    CrossrefPubMedGoogle Scholar
  • 11 Spencer S, Calverley P M, Sherwood Burge P, Jones P W. ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease . Health status deterioration in patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2001;  163 122-128
    PubMedGoogle Scholar
  • 12 Tsuji-Hayashi Y, Sizer Fitts S, Takai I et al.. Health-related quality of life among dialysis patients in Seattle and Aichi.  Am J Kidney Dis. 2001;  37 987-996
    CrossrefPubMedGoogle Scholar
  • 13 Scadding J G. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years’ observation.  BMJ. 1961;  2 1165-1172
    CrossrefPubMedGoogle Scholar
  • 14 Siltzbach L E, James D G, Neville E et al.. Course and prognosis of sarcoidosis around the world.  Am J Med. 1974;  57 847-852
    CrossrefPubMedGoogle Scholar
  • 15 Sones M, Israel H L. Course and prognosis of sarcoidosis.  Am J Med. 1960;  29 84-93
    CrossrefPubMedGoogle Scholar
  • 16 Israel H L, Fouts D W, Beggs R A. A controlled trial of prednisone treatment of sarcoidosis.  Am Rev Respir Dis. 1973;  107 609-614
    PubMedGoogle Scholar
  • 17 Hunninghake G W, Costabel U, Ando M et al.. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders.  Sarcoidosis Vasc Diffuse Lung Dis. 1999;  16 149-173
    PubMedGoogle Scholar
  • 18 Gottlieb J E, Israel H L, Steiner R M, Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy.  Chest. 1997;  111 623-631
    CrossrefPubMedGoogle Scholar
  • 19 Hunninghake G W, Gilbert S, Pueringer R et al.. Outcome of the treatment for sarcoidosis.  Am J Respir Crit Care Med. 1994;  149(4 Pt 1) 893-898
    PubMedGoogle Scholar
  • 20 Baughman R P, Lower E E, du Bois R M. Sarcoidosis.  Lancet. 2003;  361 1111-1118
    CrossrefPubMedGoogle Scholar
  • 21 Eule H, Weinecke A, Roth I, Wuthe H. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis: late results of a continuing clinical study.  Ann N Y Acad Sci. 1986;  465 695-701
    CrossrefPubMedGoogle Scholar
  • 22 Selroos O, Sellergren T L. Corticosteroid therapy of pulmonary sarcoidosis: a prospective evaluation of alternate day and daily dosage in stage II disease.  Scand J Respir Dis. 1979;  60 215-221
    PubMedGoogle Scholar
  • 23 Zaki M H, Lyons H A, Leilop L, Huang C T. Corticosteroid therapy in sarcoidosis: a five-year, controlled follow-up study.  N Y State J Med. 1987;  87 496-499
    PubMedGoogle Scholar
  • 24 Grunewald J, Shigematsu M, Nagai S et al.. T-cell receptor V gene expression in HLA-typed Japanese patients with pulmonary sarcoidosis.  Am J Respir Crit Care Med. 1995;  151 151-156
    PubMedGoogle Scholar
  • 25 Baughman R P, Costabel U, du Bois R M. Treatment of sarcoidosis.  Clin Chest Med. 2008;  29 533-548 ix-x
    CrossrefPubMedGoogle Scholar
  • 26 Judson M A. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment.  Chest. 1999;  115 1158-1165
    CrossrefPubMedGoogle Scholar
  • 27 Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Finnish Pulmonary Sarcoidosis Study Group . Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study.  Chest. 1999;  116 424-431
    CrossrefPubMedGoogle Scholar
  • 28 Gibson G J, Prescott R J, Muers M F et al.. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.  Thorax. 1996;  51 238-247
    CrossrefPubMedGoogle Scholar
  • 29 Lynch III J P, Kazerooni E A, Gay S E. Pulmonary sarcoidosis.  Clin Chest Med. 1997;  18 755-785
    CrossrefPubMedGoogle Scholar
  • 30 Mihailovic-Vucinic V, Jovanovic D. Pulmonary sarcoidosis.  Clin Chest Med. 2008;  29 459-473 viii-ix
    CrossrefPubMedGoogle Scholar
  • 31 Newman L S, Rose C S, Maier L A. Sarcoidosis.  N Engl J Med. 1997;  336 1224-1234
    CrossrefPubMedGoogle Scholar
  • 32 Nagai S, Shigematsu M, Hamada K, Izumi T. Clinical courses and prognoses of pulmonary sarcoidosis.  Curr Opin Pulm Med. 1999;  5 293-298
    CrossrefPubMedGoogle Scholar
  • 33 Neville E, Walker A N, James D G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients.  Q J Med. 1983;  52 525-533
    PubMedGoogle Scholar
  • 34 Mañá J, Salazar A, Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases.  Respiration. 1994;  61 219-225
    CrossrefPubMedGoogle Scholar
  • 35 Rømer F K. Presentation of sarcoidosis and outcome of pulmonary changes.  Dan Med Bull. 1982;  29 27-32
    PubMedGoogle Scholar
  • 36 Grunewald J, Eklund A. Löfgren’s syndrome: human leukocyte antigen strongly influences the disease course.  Am J Respir Crit Care Med. 2009;  179 307-312
    CrossrefPubMedGoogle Scholar
  • 37 Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen.  Eur Respir J. 1999;  14 1117-1122
    CrossrefPubMedGoogle Scholar
  • 38 Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis: a 15-year European study.  Am Rev Respir Dis. 1984;  130 29-32
    PubMedGoogle Scholar
  • 39 Pietinalho A, Ohmichi M, Löfroos A B, Hiraga Y, Selroos O. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan: a comparative five-year study of biopsy-proven cases.  Sarcoidosis Vasc Diffuse Lung Dis. 2000;  17 158-166
    PubMedGoogle Scholar
  • 40 Baughman R P, Winget D B, Bowen E H, Lower E E. Predicting respiratory failure in sarcoidosis patients.  Sarcoidosis Vasc Diffuse Lung Dis. 1997;  14 154-158
    PubMedGoogle Scholar
  • 41 Mañá J, Gómez-Vaquero C, Montero A et al.. Löfgren’s syndrome revisited: a study of 186 patients.  Am J Med. 1999;  107 240-245
    CrossrefPubMedGoogle Scholar
  • 42 Sharma O P. Pulmonary sarcoidosis and corticosteroids.  Am Rev Respir Dis. 1993;  147(6 Pt 1) 1598-1600
    PubMedGoogle Scholar
  • 43 Baughman C, Morin-Leisk J, Lee T. Nucleoside diphosphate kinase B (NDKB) scaffolds endoplasmic reticulum membranes in vitro.  Exp Cell Res. 2008;  314 2702-2714
    CrossrefPubMedGoogle Scholar
  • 44 Vestbo J, Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis.  Sarcoidosis. 1994;  11 123-125
    PubMedGoogle Scholar
  • 45 Judson M A. Lung transplantation for pulmonary sarcoidosis.  Eur Respir J. 1998;  11 738-744
    PubMedGoogle Scholar
  • 46 Sulica R, Teirstein A S, Kakarla S, Nemani N, Behnegar A, Padilla M L. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension.  Chest. 2005;  128 1483-1489
    CrossrefPubMedGoogle Scholar
  • 47 Ziegenhagen M W, Rothe M E, Schlaak M, Müller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis.  Eur Respir J. 2003;  21 407-413
    CrossrefPubMedGoogle Scholar
  • 48 Baughman R P, Teirstein A S, Judson M A Case Control Etiologic Study of Sarcoidosis (ACCESS) research group et al. Clinical characteristics of patients in a case control study of sarcoidosis.  Am J Respir Crit Care Med. 2001;  164(10 Pt 1) 1885-1889
    CrossrefPubMedGoogle Scholar
  • 49 Israel H L, Karlin P, Menduke H, DeLisser O G. Factors affecting outcome of sarcoidosis. Influence of race, extrathoracic involvement, and initial radiologic lung lesions.  Ann N Y Acad Sci. 1986;  465 609-618
    CrossrefPubMedGoogle Scholar
  • 50 Mihailovic-Vucinic V, Zugic V, Videnovic-Ivanov J. New observations on pulmonary function changes in sarcoidosis.  Curr Opin Pulm Med. 2003;  9 436-441
    CrossrefPubMedGoogle Scholar
  • 51 Winterbauer R H, Hutchinson J F. Use of pulmonary function tests in the management of sarcoidosis.  Chest. 1980;  78 640-647
    CrossrefPubMedGoogle Scholar
  • 52 Grutters J C, van den Bosch J M. Corticosteroid treatment in sarcoidosis.  Eur Respir J. 2006;  28 627-636
    CrossrefPubMedGoogle Scholar
  • 53 Baughman R P, Drent M, Kavuru M Sarcoidosis Investigators et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.  Am J Respir Crit Care Med. 2006;  174 795-802
    CrossrefPubMedGoogle Scholar
  • 54 Johns C J, Michele T M. The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins Hospital.  Medicine (Baltimore). 1999;  78 65-111
    CrossrefPubMedGoogle Scholar
  • 55 Yeager H, Rossman M D, Baughman R P ACCESS Research Group et al. Pulmonary and psychosocial findings at enrollment in the ACCESS study.  Sarcoidosis Vasc Diffuse Lung Dis. 2005;  22 147-153
    PubMedGoogle Scholar
  • 56 Chang B, Steimel J, Moller D R et al.. Depression in sarcoidosis.  Am J Respir Crit Care Med. 2001;  163 329-334
    CrossrefPubMedGoogle Scholar
  • 57 Michielsen H J, Peros-Golubicic T, Drent M, De Vries J. Relationship between symptoms and quality of life in a sarcoidosis population.  Respiration. 2007;  74 401-405
    CrossrefPubMedGoogle Scholar
  • 58 de Kleijn W P, De Vries J, Lower E E, Elfferich M D, Baughman R P, Drent M. Fatigue in sarcoidosis: a systematic review.  Curr Opin Pulm Med. 2009;  15 499-506
    CrossrefPubMedGoogle Scholar
  • 59 Drent M, Wirnsberger R M, de Vries J, van Dieijen-Visser M P, Wouters E F, Schols A M. Association of fatigue with an acute phase response in sarcoidosis.  Eur Respir J. 1999;  13 718-722
    CrossrefPubMedGoogle Scholar
  • 60 Wirnsberger R M, de Vries J, Wouters E F, Drent M. Clinical presentation of sarcoidosis in the Netherlands an epidemiological study.  Neth J Med. 1998;  53 53-60
    CrossrefPubMedGoogle Scholar
  • 61 De Vries J, Michielsen H, Van Heck G L, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS).  Br J Health Psychol. 2004;  9(Pt 3) 279-291
    CrossrefPubMedGoogle Scholar
  • 62 Lower E E, Harman S, Baughman R P. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.  Chest. 2008;  133 1189-1195
    CrossrefPubMedGoogle Scholar
  • 63 Baughman R P, Malhorta A, Surdulescu V, Lower E E. Armodafinil (r-modafinil) for fatigue in sarcoidosis: not just treating hypersomnolence [abstract].  Chest. 2009;  136 128S
    PubMedGoogle Scholar
  • 64 Turner G A, Lower E E, Corser B C, Gunther K L, Baughman R P. Sleep apnea in sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1997;  14(1) 61-64
    PubMedGoogle Scholar
  • 65 Mughal M M, Golish J, Kavuru M, Aladesanmi O, Ivansek N, Culver D A. Sleep apnea in sarcoidosis [abstract].  Chest. 2005;  128 230S
    PubMedGoogle Scholar
  • 66 Shah R N, Mills P R, George P J, Wedzicha J A. Upper airways sarcoidosis presenting as obstructive sleep apnoea.  Thorax. 1998;  53 232-233
    CrossrefPubMedGoogle Scholar
  • 67 Hoitsma E, De Vries J, van Santen-Hoeufft M, Faber C G, Drent M. Impact of pain in a Dutch sarcoidosis patient population.  Sarcoidosis Vasc Diffuse Lung Dis. 2003;  20 33-39
    PubMedGoogle Scholar
  • 68 Hoitsma E, Faber C G, van Kroonenburgh M J et al.. Association of small fiber neuropathy with cardiac sympathetic dysfunction in sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2005;  22 43-50
    PubMedGoogle Scholar
  • 69 Hoitsma E, Faber C G, van Santen-Hoeufft M, De Vries J, Reulen J P, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab.  Sarcoidosis Vasc Diffuse Lung Dis. 2006;  23 73-77
    PubMedGoogle Scholar
  • 70 Baughman R P, Judson M A, Teirstein A et al.. Presenting characteristics as predictors of duration of treatment in sarcoidosis.  QJM. 2006;  99 307-315
    CrossrefPubMedGoogle Scholar
  • 71 Paramothayan S, Jones P W. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review.  JAMA. 2002;  287 1301-1307
    CrossrefPubMedGoogle Scholar
  • 72 Paramothayan N S, Lasserson T J, Jones P W. Corticosteroids for pulmonary sarcoidosis.  Cochrane Database Syst Rev. 2005;  (2) CD001114
    PubMedGoogle Scholar
  • 73 Winterbauer R H, Kirtland S H, Corley D E. Treatment with corticosteroids.  Clin Chest Med. 1997;  18 843-851
    CrossrefPubMedGoogle Scholar
  • 74 Kataria Y P. Chlorambucil in sarcoidosis.  Chest. 1980;  78 36-43
    CrossrefPubMedGoogle Scholar
  • 75 Mañá J. Nuclear imaging. 67Gallium, 201thallium, 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography.  Clin Chest Med. 1997;  18 799-811
    CrossrefPubMedGoogle Scholar
  • 76 Ziegenhagen M W, Rothe M E, Zissel G, Müller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2002;  19 185-190
    PubMedGoogle Scholar
  • 77 Sodhi M, Pearson K, White E S, Culver D A. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis.  Respir Med. 2009;  103 268-273
    CrossrefPubMedGoogle Scholar
  • 78 Lower E E, Broderick J P, Brott T G, Baughman R P. Diagnosis and management of neurological sarcoidosis.  Arch Intern Med. 1997;  157 1864-1868
    CrossrefPubMedGoogle Scholar
  • 79 Alberts C, van der Mark T W, Jansen H M. Dutch Study Group on Pulmonary Sarcoidosis . Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study.  Eur Respir J. 1995;  8 682-688
    PubMedGoogle Scholar
  • 80 Erkkilä S, Fröseth B, Hellström P E et al.. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis.  Sarcoidosis. 1988;  5 106-110
    PubMedGoogle Scholar
  • 81 Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study.  J Intern Med. 1994;  236 285-290
    CrossrefPubMedGoogle Scholar
  • 82 Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis.  Sarcoidosis. 1993;  10 56-61
    PubMedGoogle Scholar
  • 83 du Bois R M, Greenhalgh P M, Southcott A M, Johnson N M, Harris T A. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study.  Eur Respir J. 1999;  13 1345-1350
    CrossrefPubMedGoogle Scholar
  • 84 Baughman R P, Iannuzzi M C, Lower E E et al.. Use of fluticasone in acute symptomatic pulmonary sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2002;  19 198-204
    PubMedGoogle Scholar
  • 85 James D G, Carstairs L S, Trowell J, Sharma O P. Treatment of sarcoidosis: report of a controlled therapeutic trial.  Lancet. 1967;  2 526-528
    PubMedGoogle Scholar
  • 86 Schutt A C, Bullington W M, Judson M A. Pharmacotherapy for pulmonary sarcoidosis: a delphi consensus study.  Respir Med. 2010;  104 713-723
    PubMedGoogle Scholar
  • 87 McKinzie B P, Bullington W M, Mazur J E, Judson M A. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations.  Am J Med Sci. 2010;  339 1-4
    CrossrefPubMedGoogle Scholar
  • 88 Yazaki Y, Isobe M, Hiroe M Central Japan Heart Study Group et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone.  Am J Cardiol. 2001;  88 1006-1010
    CrossrefPubMedGoogle Scholar
  • 89 Goldstein D S, Williams M H. Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids.  Thorax. 1986;  41 473-474
    CrossrefPubMedGoogle Scholar
  • 90 Baughman R P, Winget D B, Lower E E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.  Sarcoidosis Vasc Diffuse Lung Dis. 2000;  17 60-66
    PubMedGoogle Scholar
  • 91 Yale S H, Limper A H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.  Mayo Clin Proc. 1996;  71 5-13
    CrossrefPubMedGoogle Scholar
  • 92 Greenberg J D, Reed G, Kremer J M CORRONA Investigators et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.  Ann Rheum Dis. 2010;  69 380-386
    CrossrefPubMedGoogle Scholar
  • 93 Ellerin T, Rubin R H, Weinblatt M E. Infections and anti-tumor necrosis factor alpha therapy.  Arthritis Rheum. 2003;  48 3013-3022
    CrossrefPubMedGoogle Scholar
  • 94 Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, Sisti S. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women.  Sarcoidosis. 1988;  5 93-98
    PubMedGoogle Scholar
  • 95 Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two-year follow-up.  Ann Ital Med Int. 1990;  5(3 Pt 1) 164-168
    PubMedGoogle Scholar
  • 96 van Staa T P, Leufkens H G, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.  Osteoporos Int. 2002;  13 777-787
    CrossrefPubMedGoogle Scholar
  • 97 van Staa T P, Leufkens H G, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.  Rheumatology (Oxford). 2000;  39 1383-1389
    CrossrefPubMedGoogle Scholar
  • 98 Devogelaer J P, Goemaere S, Boonen S et al.. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.  Osteoporos Int. 2006;  17 8-19
    CrossrefPubMedGoogle Scholar
  • 99 Adler R A, Hochberg M C. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs.  Arch Intern Med. 2003;  163 2619-2624
    CrossrefPubMedGoogle Scholar
  • 100 Adams J S, Diz M M, Sharma O P. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy.  Ann Intern Med. 1989;  111 437-438
    CrossrefPubMedGoogle Scholar
  • 101 Siltzbach L E, Teirstein A S. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis.  Acta Med Scand Suppl. 1964;  425 302-308
    PubMedGoogle Scholar
  • 102 Zic J A, Horowitz D H, Arzubiaga C, King Jr L E. Treatment of cutaneous sarcoidosis with chloroquine: review of the literature.  Arch Dermatol. 1991;  127 1034-1040
    CrossrefPubMedGoogle Scholar
  • 103 Baltzan M, Mehta S, Kirkham T H, Cosio M G. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis.  Am J Respir Crit Care Med. 1999;  160 192-197
    CrossrefPubMedGoogle Scholar
  • 104 Chan E S, Cronstein B N. Molecular action of methotrexate in inflammatory diseases.  Arthritis Res. 2002;  4 266-273
    CrossrefPubMedGoogle Scholar
  • 105 Baughman R P, Lower E E. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis.  Am Rev Respir Dis. 1990;  142(6 Pt 1) 1268-1271
    PubMedGoogle Scholar
  • 106 Baughman R P, Lower E E. Alternatives to corticosteroids in the treatment of sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1997;  14 121-130
    PubMedGoogle Scholar
  • 107 Lower E E, Baughman R P. Prolonged use of methotrexate for sarcoidosis.  Arch Intern Med. 1995;  155 846-851
    CrossrefPubMedGoogle Scholar
  • 108 Veien N K, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate.  Br J Dermatol. 1977;  97 213-216
    CrossrefPubMedGoogle Scholar
  • 109 Dev S, McCallum R M, Jaffe G J. Methotrexate treatment for sarcoid-associated panuveitis.  Ophthalmology. 1999;  106 111-118
    CrossrefPubMedGoogle Scholar
  • 110 Baughman R P, Lower E E. A clinical approach to the use of methotrexate for sarcoidosis.  Thorax. 1999;  54 742-746
    CrossrefPubMedGoogle Scholar
  • 111 Webster G F, Razsi L K, Sanchez M, Shupack J L. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis.  J Am Acad Dermatol. 1991;  24 451-454
    CrossrefPubMedGoogle Scholar
  • 112 Jundt J W, Browne B A, Fiocco G P, Steele A D, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing.  J Rheumatol. 1993;  20 1845-1849
    PubMedGoogle Scholar
  • 113 van Ede A E, Laan R F, Rood M J et al.. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study.  Arthritis Rheum. 2001;  44 1515-1524
    CrossrefPubMedGoogle Scholar
  • 114 Morgan S L, Baggott J E, Vaughn W H et al.. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial.  Ann Intern Med. 1994;  121 833-841
    PubMedGoogle Scholar
  • 115 Visser K, Katchamart W, Loza E et al.. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.  Ann Rheum Dis. 2009;  68 1086-1093
    CrossrefPubMedGoogle Scholar
  • 116 Lewis S J, Ainslie G M, Bateman E D. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1999;  16 87-92
    PubMedGoogle Scholar
  • 117 Pacheco Y, Marechal C, Marechal F, Biot N, Perrin Fayolle M. Azathioprine treatment of chronic pulmonary sarcoidosis.  Sarcoidosis. 1985;  2 107-113
    PubMedGoogle Scholar
  • 118 Lennard L, Van Loon J A, Weinshilboum R M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism.  Clin Pharmacol Ther. 1989;  46 149-154
    CrossrefPubMedGoogle Scholar
  • 119 Bhat P, Cervantes-Castañeda R A, Doctor P P, Anzaar F, Foster C S. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis.  Ocul Immunol Inflamm. 2009;  17 185-190
    CrossrefPubMedGoogle Scholar
  • 120 Golshayan D, Pascual M, Vogt B. Mycophenolic acid formulations in adult renal transplantation—update on efficacy and tolerability.  Ther Clin Risk Manag. 2009;  5 341-351
    PubMedGoogle Scholar
  • 121 Baughman R P, Lower E E. Leflunomide for chronic sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2004;  21 43-48
    PubMedGoogle Scholar
  • 122 Emery P, Breedveld F C, Lemmel E M et al.. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.  Rheumatology (Oxford). 2000;  39 655-665
    CrossrefPubMedGoogle Scholar
  • 123 Bradley D A, Lower E E, Baughman R P. Diagnosis and management of spinal cord sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2006;  23 58-65
    PubMedGoogle Scholar
  • 124 Doty J D, Mazur J E, Judson M A. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen.  Chest. 2003;  124 2023-2026
    CrossrefPubMedGoogle Scholar
  • 125 Kavanaugh A F, Andrew S L, Cooper B, Lawrence E C, Huston D P. Cyclosporine therapy of central nervous system sarcoidosis.  Am J Med. 1987;  82 387
    CrossrefPubMedGoogle Scholar
  • 126 Stern B J, Schonfeld S A, Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of neurosarcoidosis with cyclosporine.  Arch Neurol. 1992;  49 1065-1072
    PubMedGoogle Scholar
  • 127 Oh J Y, Wee W R. Cyclosporine for conjunctival sarcoidosis.  Ophthalmology. 2008;  115 222
    PubMedGoogle Scholar
  • 128 Akpek E K, Ilhan-Sarac O, Green W R. Topical cyclosporin in the treatment of chronic sarcoidosis of the conjunctiva.  Arch Ophthalmol. 2003;  121 1333-1335
    CrossrefPubMedGoogle Scholar
  • 129 Bielory L, Frohman L P. Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy.  Ophthalmology. 1991;  98 1732-1736
    PubMedGoogle Scholar
  • 130 Suarez-Almazor M E, Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for treating rheumatoid arthritis.  Cochrane Database Syst Rev. 2000;  CD001157
    PubMedGoogle Scholar
  • 131 Baughman R P, Lower E E. Infliximab for refractory sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2001;  18 70-74
    PubMedGoogle Scholar
  • 132 Yee A M, Pochapin M B. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy.  Ann Intern Med. 2001;  135 27-31
    CrossrefPubMedGoogle Scholar
  • 133 Rossman M D, Newman L S, Baughman R P et al.. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2006;  23 201-208
    PubMedGoogle Scholar
  • 134 Judson M A, Baughman R P, Costabel U Centocor T48 Sarcoidosis Investigators et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.  Eur Respir J. 2008;  31 1189-1196
    CrossrefPubMedGoogle Scholar
  • 135 Carter J D, Valeriano J, Vasey F B, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab.  Am J Med. 2004;  117 277-279
    CrossrefPubMedGoogle Scholar
  • 136 Doty J D, Mazur J E, Judson M A. Treatment of sarcoidosis with infliximab.  Chest. 2005;  127 1064-1071
    CrossrefPubMedGoogle Scholar
  • 137 Moravan M, Segal B M. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil.  Neurology. 2009;  72 337-340
    CrossrefPubMedGoogle Scholar
  • 138 Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma O P. Effectiveness of infliximab in treating selected patients with sarcoidosis.  Respir Med. 2006;  100 2053-2059
    CrossrefPubMedGoogle Scholar
  • 139 Baughman R P, Lower E E, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.  Sarcoidosis Vasc Diffuse Lung Dis. 2008;  25 76-89
    PubMedGoogle Scholar
  • 140 Keane J, Gershon S, Wise R P et al.. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.  N Engl J Med. 2001;  345 1098-1104
    CrossrefPubMedGoogle Scholar
  • 141 Wallis R S, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction.  Clin Infect Dis. 2004;  39 1254-1255
    CrossrefPubMedGoogle Scholar
  • 142 Chung E S, Packer M, Lo K H, Fasanmade A A, Willerson J T. Anti-TNF Therapy Against Congestive Heart Failure Investigators . Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.  Circulation. 2003;  107 3133-3140
    CrossrefPubMedGoogle Scholar
  • 143 Sandborn W J. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.  Curr Gastroenterol Rep. 2003;  5 501-505
    CrossrefPubMedGoogle Scholar
  • 144 Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease.  Gastroenterology. 2004;  126 1593-1610
    CrossrefPubMedGoogle Scholar
  • 145 Panselinas E, Rodgers J K, Judson M A. Clinical outcomes in sarcoidosis after cessation of infliximab treatment.  Respirology. 2009;  14 522-528
    CrossrefPubMedGoogle Scholar
  • 146 Thielen A M, Barde C, Saurat J H, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.  Dermatology. 2009;  219 59-62
    CrossrefPubMedGoogle Scholar
  • 147 Marnane M, Lynch T, Scott J, Stack J, Kelly P J. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab.  J Neurol. 2009;  256 139-140
    CrossrefPubMedGoogle Scholar
  • 148 Bartelds G M, Wijbrandts C A, Nurmohamed M T et al.. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.  Ann Rheum Dis. 2007;  66 921-926
    CrossrefPubMedGoogle Scholar
  • 149 Utz J P, Limper A H, Kalra S et al.. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.  Chest. 2003;  124 177-185
    CrossrefPubMedGoogle Scholar
  • 150 Baughman R P, Lower E E, Bradley D A, Raymond L A, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial.  Chest. 2005;  128 1062-47
    CrossrefPubMedGoogle Scholar
  • 151 Kudrin A, Chilvers E R, Ginawi A et al.. Sarcoid-like granulomatous disease following etanercept treatment for RA.  J Rheumatol. 2007;  34 648-649
    PubMedGoogle Scholar
  • 152 Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.  Clin Rheumatol. 2007;  26 1969-1971
    CrossrefPubMedGoogle Scholar
  • 153 Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone.  Chest. 2003;  124 1526-1532
    CrossrefPubMedGoogle Scholar
  • 154 Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis.  Am J Respir Crit Care Med. 1997;  155 1665-1669
    CrossrefPubMedGoogle Scholar
  • 155 Park M K, Fontana J R, Babaali H et al.. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2009;  26 121-131
    PubMedGoogle Scholar
  • 156 Tavares J L, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw R J. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.  Respir Med. 1997;  91 31-39
    CrossrefPubMedGoogle Scholar
  • 157 Baughman R P, Judson M A, Teirstein A S, Moller D R, Lower E E. Thalidomide for chronic sarcoidosis.  Chest. 2002;  122 227-232
    CrossrefPubMedGoogle Scholar
  • 158 Hoyle J C, Newton H B, Katz S. Prognosis of refractory neurosarcoidosis altered by thalidomide: a case report.  J Med Case Reports. 2008;  2 27
    CrossrefPubMedGoogle Scholar
  • 159 Hammond E R, Kaplin A I, Kerr D A. Thalidomide for acute treatment of neurosarcoidosis.  Spinal Cord. 2007;  45 802-803
    CrossrefPubMedGoogle Scholar
  • 160 Judson M A, Silvestri J, Hartung C, Byars T, Cox C E. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2006;  23 51-57
    PubMedGoogle Scholar
  • 161 Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis.  Arch Dermatol. 2001;  137 69-73
    CrossrefPubMedGoogle Scholar
  • 162 Orens J B, Estenne M, Arcasoy S Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.  J Heart Lung Transplant. 2006;  25 745-755
    CrossrefPubMedGoogle Scholar
  • 163 Milman N, Burton C, Andersen C B, Carlsen J, Iversen M. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients.  Sarcoidosis Vasc Diffuse Lung Dis. 2005;  22 222-228
    PubMedGoogle Scholar
  • 164 Pigula F A, Griffith B P, Zenati M A, Dauber J H, Yousem S A, Keenan R J. Lung transplantation for respiratory failure resulting from systemic disease.  Ann Thorac Surg. 1997;  64 1630-1634
    CrossrefPubMedGoogle Scholar
  • 165 Johnson B A, Duncan S R, Ohori N P et al.. Recurrence of sarcoidosis in pulmonary allograft recipients.  Am Rev Respir Dis. 1993;  148 1373-1377
    CrossrefPubMedGoogle Scholar
  • 166 Baughman R P. Methotrexate for sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 1998;  15 147-149
    PubMedGoogle Scholar

Catherine A LazarM.D. 

Respiratory Institute, Cleveland Clinic Foundation

9500 Euclid Ave. A90, Cleveland, OH 44195

Email: lazarc@ccf.org

      >